Sean Gregory – Managing Director – Sarytogan Graphite (ASX:SGA) through its 100% owned subsiduary company, Ushtogan LLP, is the 100% owner of the Sarytogan Graphite Project. The Sarytogan Graphite Project is located in the Karaganda region of Central Kazakhstan and the exploration concession covers 70 km2. As its name suggests, the Sarytogan Graphite Project is prospective for graphite and a meaningful initial JORC compliance resource has already been delineated on the project.
Copyright 2024 – Finance News Network
07 Jun 2023 - Novonix Limited (ASX:NVX) CEO Dr Chris Burns discusses the company's joint research and development agreement with South Korean battery cell manufacturer LG Energy Solution.
06 Apr 2020 - Cyclopharm (ASX:CYC) CEO & Managing Director, James McBrayer talks about its new drug application with the US FDA for Technegas and applications beyond pulmonary embolism in chronic chronic obstructive pulmonary ( COPD ) and asthma.
28 Aug 2024 - Focused on supplying high-purity manganese for electric vehicles, Euro Manganese Limited (ASX:EMN) is advancing a project in the Czech Republic that repurposes historical mine tailings. The company's recent offtake agreement with Wildcat Discovery Technologies is a significant milestone, with more agreements and funding efforts planned for the near future.
03 Sep 2020 - Hazer Group (ASX:HZR) CEO & Managing Director, Geoff Ward talks about FY20 achievements, its final investment decision for its Commercial Development Plant to process low emissions hydrogen gas and high purity graphite production from biogas, development and commercial programs.
05 Oct 2022 - QX Resources Limited (ASX:QXR) Managing Director Stephen Promnitz discusses what brought him to QXR, and the company's assets and development stage.
05 Feb 2021 - Centuria Office REIT (ASX:COF) Fund Manager Grant Nichols discusses 1H21 highlights, the market conditions for leasing, and the outlook and trends for office markets.
18 May 2022 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow provides an update on clinical trial progression, and discusses recent agreements with WuXi Advanced Therapies and Be The Match BioTherapies.
